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Abstract
Background: Subependymal giant cell astrocytoma is a rare tumor that occurs in the wall of the lateral ventricle and
foramen of Monro and, rarely, in the third ventricle. It is one of the intracranial lesions found in tuberous sclerosis complex
(which include subependymal nodules, cortical tubers, retinal astrocytoma and subependymal giant cell astrocytoma), but
cases without such lesions have also been reported in the literature. It was described for the first time in 1908 by Vogt as
part of the typical triad of tuberous sclerosis complex. At the 2012 Washington Consensus Conference, it was
decided by the invited expert panel to document the definition of subependymal giant cell astrocytoma as a
lesion at the caudothalamic groove with either a size of more than 1 cm in any direction or a subependymal
lesion at any location that has shown serial growth on consecutive imaging regardless of size. Most subependymal
giant cell astrocytomas will show avid enhancement after contrast administration; however, a growing subependymal
lesion even in the absence of enhancement should be considered a subependymal giant cell astrocytoma.
Case presentation: We report a case of subependymal giant cell astrocytoma in a 10-year-old white girl, who had no
clinical symptoms of tuberous sclerosis. A computed tomography scan revealed a voluminous mass in her perilateral
ventricle. An extemporaneous examination was in favor of a benign ganglioglioma tumor. After fixation in 10 % neutral-
buffered formalin, embedding in paraffin and staining with hematoxylin, eosin and safran, the definitive diagnosis was
subependymal giant cell astrocytoma.
Conclusions: Subependymal giant cell astrocytoma is a rare tumor of the central nervous system whose diagnosis is
based on clinical, radiological, histological and immunohistochemical arguments. For its rarity, we must consider this
diagnosis when faced with a mass near the foramen of Monro in the pediatric population even if there are no other
features of tuberous sclerosis complex.
Keywords: Histologic analysis, Subependymal giant cell astrocytoma, Tuberous sclerosis complex
Background
Subependymal giant cell astrocytoma (SEGA) is a rare
tumor that occurs the wall of the lateral ventricle and
foramen of Monro, and, rarely, in the third ventricle. It
is one of the intracranial lesions found in tuberous scler-
osis complex (TSC); this lesion is included in the 2012
International Tuberous Sclerosis Complex Consensus
Group as a major feature (which includes subependymal
nodules, cortical tubers, retinal astrocytoma and SEGA),
but cases without such lesions have also been reported
in the literature. The histogenesis of this tumor is poorly
understood. Previous studies have reported glial (astro-
cytic or, rarely, ependymal), neuronal or mixed glial-
neuronal differentiation. We report a case of subependy-
mal giant cell astrocytoma in a child without clinical
symptoms of tuberous sclerosis. We describe the histo-
logical and immunohistochemical features of this rare
entity.
Case presentation
A 10-year-old white girl, presented with a 10-month history
of convulsive seizures without signs of intracranial
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hypertension. A computed tomography (CT) scan revealed
a voluminous mass in her perilateral ventricle with simi-
lar attenuation to that of cortical gray matter (Fig. 1a), fol-
lowing administration of a contrast product, the mass
showed marked enhancement (Fig. 1b). Surgery was per-
formed with complete resection of the tumor. An extempor-
aneous examination was in favor of a benign ganglioglioma
tumor. After fixation in 10 % neutral-buffered formalin,
embedding in paraffin and staining with hematoxylin, eosin
and safran, histologically the tumor was found to be
composed of fibrillated spindle cells and globular large cells,
with abundant eosinophilic cytoplasm, and voluminous,
eccentric nucleus, and large nucleoli, producing an aspect of
ganglion cells; mitosis, necrosis, and microvascular prolifera-
tion were not rated (Figs. 2a and 2b). Calcifications and
perivascular lymphocytes were observed. In immunohisto-
chemical studies, the spindle cells were positive for glial
fibrillary acidic protein (GFAP) (Fig. 2c) and S-100 protein
(Fig. 3a). Neurofilament and synaptophysin were negative in
either the spindle cells or the large cells (Fig. 3b), and KI67
was not detectable (Fig 3c). An examination that included a
dermatological evaluation, a retinal examination, and body
imaging revealed no stigmata of tuberous sclerosis. The
postoperative course was straightforward.
Discussion
Subependymal giant cell astrocytoma (SEGA) is a slowly
growing tumor of unknown histogenesis mainly arising
in the periventricular regions adjacent to the foramen of
Monro [1, 2], which causes increased intracranial pres-
sure, seizures, and focal neurologic signs. The incidence
of SEGAs in tuberous sclerosis (TSC) varies from 5 % to
14 %, and may also be detected prenatally or at birth,
although they are much more likely to arise during
childhood or adolescence and it would be unusual for
one to occur after the age of 20 years if not previously
present [1, 3]. At the 2012 Washington Consensus Con-
ference, it was decided by the invited expert panel to
document the definition of SEGAs as a lesion at the
caudothalamic groove with either a size of more than 1
cm in any direction or a subependymal lesion at any
location that has shown serial growth on consecutive
imaging regardless of size. Most SEGAs will show avid
enhancement after contrast administration; however, a
growing subependymal lesion even in the absence of
enhancement should be considered a SEGA [4, 2].
Although histologically confirmed SEGA is considered
pathognomonic for TSC, there are reports of patients
with this tumor who have none of the other stigmata of
Fig. 1 Computed tomography scan revealing a voluminous mass in the perilateral ventricle with similar attenuation to that of cortical gray
matter (a), following administration of a contrast product, the mass showed marked enhancement (b)
a b c
Fig. 2 Tumor composed of spindle cells and globular large cells, producing an aspect of ganglion cells: (a) hematoxylin-eosin-safran × 100, (b)
hematoxylin-eosin-safran × 20, (c) immunostaining: glial fibrillary acidic protein positive
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tuberous sclerosis complex [3, 5]. This is an autosomal
dominant phacomatosis, due, in 60 % of cases, to spon-
taneous mutation in two tumor suppressor genes (TSC1
and TSC2) [6–8]. It is manifested by the development of
benign tumors in many organs (heart, kidney, skin, and
brain). The cutaneous and neurological involvement is
almost constant. The central nervous system is represented
by cortical tubers, subependymal nodules, subependymal
giant cell astrocytomas and retinal astrocytoma. The risk of
mental retardation is high in this condition especially when
associated with seizures in the first year of life [9–11]. It
typically affects patients during childhood and adolescence;
neonatal cases have also been reported [11].
The clinical features of SEGA are due to hydrocephalus,
raised intracranial pressure and seizures. Hydrocephalus
occurs due to obstruction of the cerebrospinal fluid path-
way by the tumor itself [11, 12]. As the association of
SEGA and tuberous sclerosis is common, the characteristic
symptoms of this disease are often present and must be in-
vestigated. In some cases, the SEGA can usher in the
absence of clinical stigmata of tuberous sclerosis [7, 10, 13].
CT and magnetic resonance (MR) imaging characteristics
are usually nonspecific, and the location of the mass and
the patient’s age are useful indicators of the specific tissue
diagnosis [9, 13, 14]. Although nonspecific, the CT and MR
findings objectify a well-circumscribed mass at the foramen
of Monro, which frequently exhibits partial calcification or
cyst formation. Enhancement following contrast adminis-
tration is strong but inhomogeneous [9, 15].
Histologically, subependymal giant cell astrocytomas are
characterized by triple cell components distributed over a
fibrillar background; large astrocyte-like cells with perivas-
cular pseudopalisading and often calcification. There is a
wide spectrum of cells within the tumor cells, ranging from
gemistocytic astrocytes to long fibrillated and spindle cells,
as well as large giant cells, some of them with a ganglionic
appearance with large eosinophilic and finely granular cyto-
plasm, the nucleus are rounded or oval, large, and eccentric.
Increased mitotic activity, pleomorphism, occasional endo-
thelial proliferation, and necrosis did not have any
prognostic value [16, 7], perivascular lymphocytic inflamma-
tory infiltrate is usually found, as noted in our case [12, 17].
Immunohistochemical studies have demonstrated a
mixed glial and neuronal differentiation of subependymal
giant cell astrocytoma [13–19], leading some to hypothesize
that these lesions arise from multipotent progenitor cells
within the germinal mantle of the developing brain [11, 13].
In our case, only astroglial differentiation was demonstrated
by detectable levels of GFAP and S100 protein immunore-
activity and absence of both synaptophysin and neurofila-
ment immunoreactivity. These findings are in agreement
with literature data, which demonstrated that astroglial
differentiation predominantly occurs in cases of SEGA in
asymptomatic tuberous sclerosis, in contrast to both
glial and neuronal differentiation in tuberous sclerosis-
associated cases [11, 17, 19].
Radical and early surgery is the treatment of choice, it is
associated with a better prognosis without complications,
due partly to the intracranial hypertension and the associ-
ation with tuberous sclerosis and the surgical procedure
itself, which influences the functional and vital prognosis
[5, 20, 21]. Recurrences are related to incomplete surgery.
The progress of targeted therapies has a new perspective
in SEGA’s treatment; it is the inhibitor of mTOR (everoli-
mus) that indicates from the age of 12 months in subepen-
dymal giant cell astrocytoma associated with tuberous
sclerosis complex requiring therapeutic intervention but
not eligible for surgical resection. This molecule can reduce
the volume of the tumor without destroying it entirely.
Furthermore, discontinuation of the drug led to a resump-
tion of tumor growth [22].
Conclusions
Subependymal giant cell astrocytoma is a rare tumor of
the central nervous system whose diagnosis is based on
clinical, radiological, histological and immunohistochemi-
cal arguments. It should be included in the differential
diagnosis of a mass near the foramen of Monro even if
there are no other features of tuberous sclerosis complex.
a b c
Fig. 3 Tumor composed of spindle cells and globular large cells, producing an aspect of ganglion cells: (a) immunostaining: PS100 positive (b)
immunostaining: synaptophysin negative, (c) immunostaining: KI67 0 %
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